PRL-3 gene expression in normal PCs, MM cell lines, and PCs from patients with MGUS, SMM, and MM. (A) PRL-3 gene expression in PCs from 22 control subjects with normal BM, 44 patients with MGUS, 12 patients with SMM, 256 patients with MM, and in 45 myeloma cell lines. The Affymetrix signal, a quantitative measure of gene expression, is indicated on the y-axis. The level of expression of PRL-3 in each sample is indicated by the height of the bar. Samples are ordered from the lowest to highest level of expression of the PRL-3 gene, from left to the right on the x-axis. The table shows the results of the chi-square test by comparison of the Affymetrix Detection signal among the groups. The numbers in boxes above panels A and B indicate the Affymetrix annotation number of the PRL-3 gene. (B) PRL-3 gene expression in MM subgroups. The correlation of the Affymetrix signal (expression level: vertical axis) of PRL-3 with 7 myeloma subgroups from the 256 cases is shown on the top panel. The expression levels for PRL-3 are proportional to the height of each bar (representing a single patient sample). PRL-3 was significantly overexpressed in the proliferation (PR), MMSET/FGFR3, and low-bone disease (LB) groups. The table in the bottom panel shows the chi-square test for Affymetrix detection of PRL-3 among the 7 subgroups.